nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

09.03.2016 | Review Article

Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons

verfasst von: Laura Evangelista, Francesco Bertoldo, Francesco Boccardo, Giario Conti, Ilario Menchi, Francesco Mungai, Umberto Ricardi, Emilio Bombardieri

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Different therapeutic options for the management of prostate cancer (PC) have been developed, and some are successful in providing crucial improvement in both survival and quality of life, especially in patients with metastatic castration-resistant PC. In this scenario, diverse combinations of radiopharmaceuticals (for targeting bone, cancer cells and receptors) and nuclear medicine modalities (e.g. bone scan, SPECT, SPECT/CT, PET and PET/CT) are now available for imaging bone metastases. Some radiopharmaceuticals are approved, currently available and used in the routine clinical setting, while others are not registered and are still under evaluation, and should therefore be considered experimental. On the other hand, radiologists have other tools, in addition to CT, that can better visualize bone localization and medullary involvement, such as multimodal MRI. In this review, the authors provide an overview of current management of advanced PC and discuss the choice of diagnostic modality for the detection of metastatic skeletal lesions in different phases of the disease. In addition to detection of bone metastases, the evaluation of response to therapy is another critical issue, since it remains one of the most important open questions that a multidisciplinary team faces when optimizing the management of PC. The authors emphasize the role of nuclear modalities that can presently be used in clinical practice, and also look at future perspectives based on relevant clinical data with novel radiopharmaceuticals.

Gater A, Abetz-Webb L, Battersby C, Parasuraman B, McIntosh S, Nathan F, et al. Pain in castration-resistant prostate cancer with bone metastases: a qualitative study. Health Qual Life Outcomes. 2011;9:88. doi:10.1186/1477-7525-9-88.PubMedPubMedCentralCrossRef

Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180–92. doi:10.1111/j.1742-1241.2011.02799.x.PubMedCrossRef

Lee RJ, Saylor PJ, Smith MR. Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer. 2010;8:29–36. doi:10.3816/CGC.2010.n.005.PubMedPubMedCentralCrossRef

Lipton A, Cook R, Brown J, Body JJ, Smith M, Coleman R. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses. Clin Oncol (R Coll Radiol). 2013;25:217–26. doi:10.1016/j.clon.2012.11.004.CrossRef

Saad F, Clarke N, Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur Urol. 2006;49:429–40. doi:10.1016/j.eururo.2005.12.045.PubMedCrossRef

Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23:2918–25. doi:10.1200/JCO.2005.01.529.PubMedCrossRef

Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s–9s. doi:10.1158/1078-0432.CCR-06-0931.PubMedCrossRef

Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419–24. doi:10.1056/NEJM198908173210702.PubMedCrossRef

Doctor SM, Tsao CK, Godbold JH, Galsky MD, Oh WK. Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer. Cancer. 2014;120:833–9. doi:10.1002/cncr.28494.PubMedCrossRef

10.

Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184:162–7. doi:10.1016/j.juro.2010.03.034.PubMedCrossRef

11.

Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168:1005–7. doi:10.1097/01.ju.0000024395.86788.cc.PubMedCrossRef

12.

Onukwugha E, Yong C, Mullins CD, Seal B, McNally D, Hussain A. Skeletal-related events and mortality among older men with advanced prostate cancer. J Geriatr Oncol. 2014;5:281–9. doi:10.1016/j.jgo.2014.03.002.PubMedCrossRef

13.

Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, et al. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer. 2013;21:3279–86. doi:10.1007/s00520-013-1887-3.PubMedCrossRef

14.

Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999;17:948–57.PubMed

15.

Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, et al. Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999–2006. Breast Cancer Res Treat. 2012;131:231–8. doi:10.1007/s10549-011-1721-x.PubMedCrossRef

16.

Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61:195–202.PubMedCrossRef

17.

Tait C, Moore D, Hodgson C, Brown M, Morris T, Growcott J, et al. Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. BJU Int. 2014;114:E70–3. doi:10.1111/bju.12717.PubMedCrossRef

18.

Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, et al. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology. 2014;271:220–9. doi:10.1148/radiol.13130625.PubMedCrossRef

19.

Beheshti M, Mottaghy FM, Payche F, Behrendt FF, Van den Wyngaert T, Fogelman I, et al. (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging. Eur J Nucl Med Mol Imaging. 2015;42:1767–77. doi:10.1007/s00259-015-3138-y.PubMedCrossRef

20.

Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80. doi:10.1016/j.eururo.2007.09.002.PubMedCrossRef

21.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Prostate cancer. 2015. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 21 Oct 2015.

22.

Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT. Prostate carcinoma presentation, diagnosis, and staging: an update from the National Cancer Data Base. Cancer. 2003;98:1169–78. doi:10.1002/cncr.11635.PubMedCrossRef

23.

Jacobs SC. Spread of prostatic cancer to bone. Urology. 1983;21:337–44.PubMedCrossRef

24.

Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: “RECIST”ing a step backwards. Clin Cancer Res. 2005;11:5223–32. doi:10.1158/1078-0432.CCR-05-0109.PubMedPubMedCentralCrossRef

25.

Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol. 2000;31:578–83.PubMedCrossRef

26.

Freedland SJ, Richhariya A, Wang H, Chung K, Shore ND. Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. Urology. 2012;80:293–8. doi:10.1016/j.urology.2012.04.007.PubMedCrossRef

27.

Tofe AJ, Francis MD, Harvey WJ. Correlation of neoplasms with incidence and localization of skeletal metastases: an analysis of 1355 diphosphonate bone scans. J Nucl Med. 1975;16:986–9.PubMed

28.

Wang CY, Wu GY, Shen MJ, Cui KW, Shen Y. Comparison of distribution characteristics of metastatic bone lesions between breast and prostate carcinomas. Oncol Lett. 2013;5:391–7. doi:10.3892/ol.2012.1005.PubMed

29.

Wilson MA, Calhoun FW. The distribution of skeletal metastases in breast and pulmonary cancer: concise communication. J Nucl Med. 1981;22:594–7.PubMed

30.

Sher HI. The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). ASCO Annual Meeting 2015. Chicago; 2015.

31.

Ottewell PD, Wang N, Meek J, Fowles CA, Croucher PI, Eaton CL, et al. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr Relat Cancer. 2014;21:769–81. doi:10.1530/ERC-14-0199.PubMedCrossRef

32.

Wang N, Docherty FE, Brown HK, Reeves KJ, Fowles AC, Ottewell PD, et al. Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models. J Bone Miner Res. 2014;29:2688–96. doi:10.1002/jbmr.2300.PubMedCrossRef

33.

Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer. 1997;80:1581–7.PubMedCrossRef

34.

Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 1991;68:74–80.PubMedCrossRef

35.

Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol. 2008;180:1154–60. doi:10.1016/j.juro.2008.04.140.PubMedPubMedCentralCrossRef

36.

Fang J, Xu Q. Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics. Clin Transl Oncol. 2015;17:173–9. doi:10.1007/s12094-014-1247-x.PubMedCrossRef

37.

Jayasekera J, Onukwugha E, Bikov K, Mullins CD, Seal B, Hussain A. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. Pharmacoeconomics. 2014;32:173–91. doi:10.1007/s40273-013-0121-y.PubMedCrossRef

38.

Boccardo F. The MAINSAIL trial: an expected failure. Lancet Oncol. 2015;16:355–6. doi:10.1016/S1470-2045(15)70058-6.PubMedCrossRef

39.

Horwich A, Parker C, de Reijke T, Kataja V, Group EGW. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi106–14. doi:10.1093/annonc/mdt208.PubMedCrossRef

40.

James MD, Sydes MR, Mason MD. Docetaxel (DOC) +/− zoledronic acid for hormone-naive prostate cancer: first available results from STAMPEDE and treatment effects within subgroups (NCT00268476). Eur J Cancer. 2015;51:abstract 19LBC:S719.

41.

Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20. doi:10.1056/NEJMoa041318.PubMedCrossRef

42.

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46. doi:10.1056/NEJMoa1503747.PubMedPubMedCentralCrossRef

43.

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. doi:10.1056/NEJMoa040720.PubMedCrossRef

44.

van Soest RJ, Nieuweboer AJ, de Morree ES, Chitu D, Bergman AM, Goey SH, et al. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2015;51:2562–9. doi:10.1016/j.ejca.2015.07.037.

45.

Attard G, Reid AH, A’Hern R, Parker C, Oommen NB, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742–8. doi:10.1200/JCO.2008.20.0642.PubMedPubMedCentralCrossRef

46.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33. doi:10.1056/NEJMoa1405095.PubMedPubMedCentralCrossRef

47.

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. doi:10.1056/NEJMoa1014618.PubMedPubMedCentralCrossRef

48.

Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738–46. doi:10.1016/S1470-2045(14)70183-4.PubMedCrossRef

49.

Parker C, Gillessen S, Heidenreich A, Horwich A, Committee EG. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v69–77. doi:10.1093/annonc/mdv222.PubMedCrossRef

50.

Saad F, McKiernan J, Eastham J. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol. 2006;24:4–12. doi:10.1016/j.urolonc.2005.06.020.PubMedCrossRef

51.

Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007;25:1423–36. doi:10.1200/JCO.2006.09.5281.PubMedCrossRef

52.

Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79:965–76. doi:10.1016/j.ijrobp.2010.11.026.PubMedCrossRef

53.

Fairchild A, Barnes E, Ghosh S, Ben-Josef E, Roos D, Hartsell W, et al. International patterns of practice in palliative radiotherapy for painful bone metastases: evidence-based practice? Int J Radiat Oncol Biol Phys. 2009;75:1501–10. doi:10.1016/j.ijrobp.2008.12.084.PubMedCrossRef

54.

Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach 3rd M, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005;97:798–804. doi:10.1093/jnci/dji139.PubMedCrossRef

55.

Konski A. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60:1373–8. doi:10.1016/j.ijrobp.2004.05.053.PubMedCrossRef

56.

Ricardi U, Filippi AR, Franco P. New concepts and insights into the role of radiation therapy in extracranial metastatic disease. Expert Rev Anticancer Ther. 2013;13:1145–55. doi:10.1586/14737140.2013.846829.PubMedCrossRef

57.

Yoon F, Morton GC. Single fraction radiotherapy versus multiple fraction radiotherapy for bone metastases in prostate cancer patients: comparative effectiveness. Cancer Manag Res. 2014;6:451–7. doi:10.2147/CMAR.S44940.PubMedPubMedCentralCrossRef

58.

van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437–49. doi:10.1093/annonc/mdm056.CrossRef

59.

Portenoy RK, Koh M. Cancer pain syndromes. In: Bruera E, Portenoy RK, editors. Cancer pain assessment and management. Cambridge: Cambridge University Press; 2010.

60.

van Herk R, van Dijk M, Baar FP, Tibboel D, de Wit R. Observation scales for pain assessment in older adults with cognitive impairments or communication difficulties. Nurs Res. 2007;56:34–43.PubMedCrossRef

61.

Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol. 1998;16:1835–43.PubMed

62.

Thuret R, Massard C, Gross-Goupil M, Escudier B, Di Palma M, Bossi A, et al. The postchemotherapy PSA surge syndrome. Ann Oncol. 2008;19:1308–11. doi:10.1093/annonc/mdn062.PubMedCrossRef

63.

Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59. doi:10.1200/JCO.2007.12.4487.PubMedPubMedCentralCrossRef

64.

Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol. 2002;20:850–6.PubMedCrossRef

65.

Koizumi M, Yonese J, Fukui I, Ogata E. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int. 2001;87:348–51.PubMedCrossRef

66.

Koopmans N, de Jong IJ, Breeuwsma AJ, van der Veer E. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol. 2007;178:849–53. doi:10.1016/j.juro.2007.05.029.PubMedCrossRef

67.

Zafeirakis AG, Papatheodorou GA, Limouris GS. Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases. Nucl Med Commun. 2010;31:249–53. doi:10.1097/MNM.0b013e328335a5ed.PubMedCrossRef

68.

Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23:4925–35. doi:10.1200/JCO.2005.06.091.PubMedCrossRef

69.

Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2006;12:3361–7. doi:10.1158/1078-0432.CCR-06-0269.PubMedCrossRef

70.

Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, et al. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology. 2007;70:315–9. doi:10.1016/j.urology.2007.03.071.PubMedPubMedCentralCrossRef

71.

Metwalli AR, Rosner IL, Cullen J, Chen Y, Brand T, Brassell SA, et al. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer. Urol Oncol. 2014;32:761–8. doi:10.1016/j.urolonc.2014.03.024.PubMedPubMedCentralCrossRef

72.

Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate. 2006;66:503–13. doi:10.1002/pros.20311.PubMedCrossRef

73.

Michaelson MD, Marujo RM, Smith MR. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res. 2004;10:2705–8.PubMedCrossRef

74.

Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P, et al. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int. 2012;23:2425–33. doi:10.1007/s00198-012-2049-z.PubMedPubMedCentralCrossRef

75.

Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, et al. Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol. 2011;80:411–32. doi:10.1016/j.critrevonc.2011.02.005.PubMedCrossRef

76.

Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391–420. doi:10.1007/s00198-010-1501-1.PubMedCrossRef

77.

Lecouvet FE, Geukens D, Stainier A, Jamar F, Jamart J, d’Othee BJ, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol. 2007;25:3281–7. doi:10.1200/JCO.2006.09.2940.PubMedCrossRef

78.

Ketelsen D, Rothke M, Aschoff P, Merseburger AS, Lichy MP, Reimold M, et al. Detection of bone metastasis of prostate cancer – comparison of whole-body MRI and bone scintigraphy. Rofo. 2008;180:746–52. doi:10.1055/s-2008-1027479.PubMedCrossRef

79.

Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F, et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol. 2012;62:68–75. doi:10.1016/j.eururo.2012.02.020.PubMedCrossRef

80.

Luboldt W, Kufer R, Blumstein N, Toussaint TL, Kluge A, Seemann MD, et al. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology. 2008;249:1017–25. doi:10.1148/radiol.2492080038.PubMedCrossRef

81.

Venkitaraman R, Cook GJ, Dearnaley DP, Parker CC, Khoo V, Eeles R, et al. Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J Med Imaging Radiat Oncol. 2009;53:241–7. doi:10.1111/j.1754-9485.2009.02070.x.PubMedCrossRef

82.

Wang X, Zhang C, Jiang X. Prospective study of bone metastasis from prostate cancer: comparison between large field diffusion-weighted imaging and bone scintigraphy. Chin J Radiol. 2009;43:131–5.

83.

Gutzeit A, Doert A, Froehlich JM, Eckhardt BP, Meili A, Scherr P, et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skelet Radiol. 2010;39:333–43. doi:10.1007/s00256-009-0789-4.CrossRef

84.

Mosavi F, Johansson S, Sandberg DT, Turesson I, Sorensen J, Ahlstrom H. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol. 2012;199:1114–20. doi:10.2214/AJR.11.8351.PubMedCrossRef

85.

Stecco A, Lombardi M, Leva L, Brambilla M, Negru E, Delli Passeri S, et al. Diagnostic accuracy and agreement between whole-body diffusion MRI and bone scintigraphy in detecting bone metastases. Radiol Med. 2013;118:465–75. doi:10.1007/s11547-012-0870-2.PubMedCrossRef

86.

Galasko CS. Diagnosis of skeletal metastases and assessment of response to treatment. Clin Orthop Relat Res. 1995;312:64–75.PubMed

87.

Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942–53. doi:10.1200/JCO.2004.08.181.PubMedCrossRef

88.

Bauerle T, Semmler W. Imaging response to systemic therapy for bone metastases. Eur Radiol. 2009;19:2495–507. doi:10.1007/s00330-009-1443-1.PubMedCrossRef

89.

Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010;1:80–92.PubMedPubMedCentralCrossRef

90.

Schmidt GP, Reiser MF, Baur-Melnyk A. Whole-body MRI for the staging and follow-up of patients with metastasis. Eur J Radiol. 2009;70:393–400. doi:10.1016/j.ejrad.2009.03.045.PubMedCrossRef

91.

Pasoglou V, Michoux N, Peeters F, Larbi A, Tombal B, Selleslagh T, et al. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease. Radiology. 2015;275:155–66. doi:10.1148/radiol.14141242.PubMedCrossRef

92.

Koh DM, Takahara T, Imai Y, Collins DJ. Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. Magn Reson Med Sci. 2007;6:211–24.PubMedCrossRef

93.

Reischauer C, Froehlich JM, Koh DM, Graf N, Padevit C, John H, et al. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps – initial observations. Radiology. 2010;257:523–31. doi:10.1148/radiol.10092469.PubMedCrossRef

94.

Koh DM, Blackledge M, Collins DJ, Padhani AR, Wallace T, Wilton B, et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol. 2009;19:2728–38. doi:10.1007/s00330-009-1469-4.PubMedCrossRef

95.

Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer. 2014;50:1617–27. doi:10.1016/j.ejca.2014.03.010.PubMedCrossRef

96.

Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20. doi:10.1007/s00259-013-2525-5.PubMedCrossRef

97.

Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.PubMed

98.

Nanni C, Schiavina R, Brunocilla E, Borghesi M, Ambrosini V, Zanoni L, et al. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clin Genitourin Cancer. 2014;12:106–10. doi:10.1016/j.clgc.2013.08.002.PubMedCrossRef

99.

Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol. 2010;57:551–8. doi:10.1016/j.eururo.2009.12.023.PubMedCrossRef

100.

Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, et al. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol. 2012;30:519–24. doi:10.1200/JCO.2011.36.5791.PubMedPubMedCentralCrossRef

101.

Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the bone scan index. Eur Urol. 2012;62:78–84. doi:10.1016/j.eururo.2012.01.037.PubMedPubMedCentralCrossRef

102.

Gamez-Cenzano C, Pino-Sorroche F. Standardization and quantification in FDG-PET/CT imaging for staging and restaging of malignant disease. PET Clin. 2014;9:117–27. doi:10.1016/j.cpet.2013.10.003.PubMedCrossRef

103.

Garcia JR, Moreno C, Valls E, Cozar P, Bassa P, Soler M, et al. Diagnostic performance of bone scintigraphy and (11)C-choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer. Rev Esp Med Nucl Imagen Mol. 2015;34:155–61. doi:10.1016/j.remn.2014.08.001.PubMed

104.

Poulsen MH, Petersen H, Hoilund-Carlsen PF, Jakobsen JS, Gerke O, Karstoft J, et al. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [18F]choline positron emission tomography(PET)/computed tomography (CT) and [18F]NaF PET/CT. BJU Int. 2014;114:818–23. doi:10.1111/bju.12599.PubMedCrossRef

105.

Iagaru A, Mittra E, Dick DW, Gambhir SS. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol. 2012;14:252–9. doi:10.1007/s11307-011-0486-2.PubMedCrossRef

106.

Damle NA, Bal C, Bandopadhyaya GP, Kumar L, Kumar P, Malhotra A, et al. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan. Jpn J Radiol. 2013;31:262–9. doi:10.1007/s11604-013-0179-7.PubMedCrossRef

107.

Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Turler A, et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2014;41:59–67. doi:10.1007/s00259-013-2532-6.PubMedCrossRef

108.

Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F, et al. (18)F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun. 2011;32:168–76. doi:10.1097/MNM.0b013e3283412ef5.PubMedCrossRef

109.

Takesh M, Odat Allh K, Adams S, Zechmann C. Diagnostic role of (18)F-FECH-PET/CT compared with bone scan in evaluating the prostate cancer patients referring with biochemical recurrence. ISRN Oncol. 2012;2012:815234. doi:10.5402/2012/815234.PubMedPubMedCentral

110.

Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2009;11:446–54. doi:10.1007/s11307-009-0217-0.PubMedCrossRef

111.

Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med. 2006;36:73–92. doi:10.1053/j.semnuclmed.2005.09.002.PubMedCrossRef

112.

McCarthy M, Siew T, Campbell A, Lenzo N, Spry N, Vivian J, et al. (18)F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging. 2011;38:14–22. doi:10.1007/s00259-010-1579-x.PubMedCrossRef

113.

Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766–74. doi:10.1007/s00259-008-0788-z.PubMedCrossRef

114.

Fuccio C, Castellucci P, Schiavina R, Santi I, Allegri V, Pettinato V, et al. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med. 2010;24:485–92. doi:10.1007/s12149-010-0390-x.PubMedCrossRef

115.

Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L, et al. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:13–26. doi:10.1007/s00259-011-1920-z.PubMedCrossRef

116.

Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N, et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med. 2014;55:223–32. doi:10.2967/jnumed.113.123018.PubMedCrossRef

117.

Hetzel M, Hetzel J, Arslandemir C, Nussle K, Schirrmeister H. Reliability of symptoms to determine use of bone scans to identify bone metastases in lung cancer: prospective study. BMJ. 2004;328:1051–2. doi:10.1136/bmj.328.7447.1051.PubMedPubMedCentralCrossRef

118.

Schirrmeister H, Arslandemir C, Glatting G, Mayer-Steinacker R, Bommer M, Dreinhofer K, et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31:964–8. doi:10.1007/s00259-004-1492-2.PubMedCrossRef

119.

Steinborn MM, Heuck AF, Tiling R, Bruegel M, Gauger L, Reiser MF. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr. 1999;23:123–9.PubMedCrossRef

120.

Caffo O, Maines F, Donner D, Veccia A, Chierichetti F, Galligioni E. Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients. Clin Genitourin Cancer. 2014;12:312–6. doi:10.1016/j.clgc.2014.03.004.PubMedCrossRef

121.

De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio SL, Menna C, et al. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging. 2015;42:1276–83. doi:10.1007/s00259-015-3042-5.PubMedCrossRef

122.

De Giorgi U, Caroli P, Burgio SL, Menna C, Conteduca V, Bianchi E, et al. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget. 2014;5:12448–58.PubMedPubMedCentralCrossRef

123.

Ceci F, Castellucci P, Graziani T, Schiavina R, Renzi R, Borghesi M, et al. (11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. Eur J Nucl Med Mol Imaging. 2016:43:84–91. doi:10.1007/s00259-015-3177-4.PubMedCrossRef

124.

Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, et al. Castration-resistant prostate cancer: AUA guideline. American Urological Association; 2015.

125.

Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27:5431–8. doi:10.1200/JCO.2008.20.1228.PubMedCrossRef

126.

Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med. 2011;52:81–9. doi:10.2967/jnumed.110.077941.PubMedCrossRef

127.

Wade AA, Scott JA, Kuter I, Fischman AJ. Flare response in 18F-fluoride ion PET bone scanning. AJR Am J Roentgenol. 2006;186:1783–6. doi:10.2214/AJR.05.0225.PubMedCrossRef

128.

McNamara MA, George DJ. Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report. BMC Cancer. 2015;15:371. doi:10.1186/s12885-015-1390-y.PubMedPubMedCentralCrossRef

129.

Jadvar H, Desai B, Ji L, Groshen S, Mills J, Murray R, et al. Prediction of hormonal resistance in metastatic prostate cancer with FDG PET/CT. J Nucl Med. 2015;56 Suppl 3:Abstract 1451.

130.

Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209. doi:10.1007/s00259-014-2949-6.PubMedCrossRef

131.

Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887–97. doi:10.1007/s00259-013-2660-z.PubMedCrossRef

132.

Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015;68:530–4. doi:10.1016/j.eururo.2015.04.034.PubMedCrossRef

133.

Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185–90. doi:10.2967/jnumed.115.160382.PubMedCrossRef

134.

Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, et al. Is there a role for (11)C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging. 2011;38:55–63. doi:10.1007/s00259-010-1604-0.PubMedCrossRef

135.

Ceci F, Castellucci P, Graziani T, Schiavina R, Chondrogiannis S, Bonfiglioli R, et al. 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer. Clin Nucl Med. 2015;40:e265–70. doi:10.1097/RLU.0000000000000783.PubMedCrossRef

136.

Cimitan M, Evangelista L, Hodolic M, Mariani G, Baseric T, Bodanza V, et al. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1000 patients. J Nucl Med. 2015;56:209–15. doi:10.2967/jnumed.114.141887.PubMedCrossRef

137.

Evangelista L, Cimitan M, Zattoni F, Guttilla A, Zattoni F, Saladini G. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- to high-risk prostate cancer: a retrospective analysis. Scand J Urol. 2015;49:345–53. doi:10.3109/21681805.2015.1005665.PubMedCrossRef

138.

Mitchell CR, Lowe VJ, Rangel LJ, Hung JC, Kwon ED, Karnes RJ. Operational characteristics of (11)C-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol. 2013;189:1308–13. doi:10.1016/j.juro.2012.10.069.PubMedCrossRef

139.

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26:1589–604. doi:10.1093/annonc/mdv257.PubMedPubMedCentralCrossRef

Titel: Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons
verfasst von: Laura Evangelista
Francesco Bertoldo
Francesco Boccardo
Giario Conti
Ilario Menchi
Francesco Mungai
Umberto Ricardi
Emilio Bombardieri
Publikationsdatum: 09.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3350-4

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons

Abstract

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2016

Intratumoral heterogeneity of 18F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma

Book Review on: Radioguided Surgery: Current Applications and Innovative Directions in Clinical Practice. Ken Hermann, Omgo E. Neiweg and Stephen P. Povoski (eds). Springer, Heidelberg, Germany

PET/CT with 18F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?

Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?

Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM)

Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer